24/7 Market News Snapshot 12 August, 2025 – Cognition Therapeutics, Inc. Common Stock (NASDAQ:CGTX)

August 12, 2025

DENVER, Colo., 12 August, 2025 (www.247marketnews.com) – (NASDAQ:CGTX) are discussed in this article.
Cognition Therapeutics, Inc. (NASDAQ:CGTX) has seen a remarkable surge in its stock price, soaring nearly 45% to $1.245 after opening at $0.86, following a previous closing price of $0.859. With a trading volume exceeding 10.88 million shares, the market reaction underscores increasing investor interest and confidence in the company. This heightened momentum aligns with the company’s recent advancements in its drug development pipeline, particularly concerning its investigational treatment, zervimesine (CT1812).

The U.S. Food and Drug Administration (FDA) has provided critical validation of Cognition Therapeutics’ strategic approach, particularly following a pivotal end-of-Phase 2 meeting regarding the Phase 3 development plans for zervimesine. Targeting adults diagnosed with mild-to-moderate Alzheimer’s disease who exhibit lower levels of the biomarker p-tau217, the Phase 3 program is designed to optimize patient enrollment and study efficacy. The FDA’s endorsement of this enrichment strategy signals a clear pathway for a potential future New Drug Application (NDA) submission.

Dr. Anthony Caggiano, Chief Medical Officer and Head of R&D at Cognition, emphasized the importance of this FDA alignment, stating that it enables the company to focus on patients who may benefit most from treatment. This Phase 3 program will employ a randomized, double-blind design, administering either 100mg of zervimesine or a placebo daily over six months, with a comprehensive evaluation of safety, efficacy, and biomarker impact.

Lisa Ricciardi, President and CEO, expressed optimism regarding the FDA’s insights, highlighting that two six-month Phase 3 studies could sufficiently support an NDA. Cognition Therapeutics remains committed to pioneering innovative solutions for neurodegenerative disorders, reinforcing its position as a leader in therapeutic development aimed at addressing significant unmet medical needs in the central nervous system disorder landscape.

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.